Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870164 | 0.91 | KDM4E (0.58) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7140763 | 0.89 | MAPT (0.68) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7042283 | 0.88 | MAPT (0.56) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7039193 | 0.88 | LMNA (0.61) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7041864 | 0.85 | HDAC6 (0.44) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7045952 | 0.83 | TDP2 (0.52) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7149095 | 0.82 | MAPT (0.54) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7143995 | 0.81 | ADORA1 (0.53) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7146900 | 0.81 | PDE4D (0.50) | KDM4EMAPTPDE4DNPC1RAB9A | |
| SCHEMBL7145323 | 0.80 | PDE4D (0.48) | KDM4EMAPTPDE4DNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |